Replies to post #105129 on Biotech Values

[bladerunner1717]

David,

What are your thoughts on IMGN here?

Do you see the seeming validation of SGEN's ADC technology having any effect on IMGN?

Why does the CMS questionnaire on Provenge look far more detailed and complex than the FDA hearings on Provenge? (It sounds like the approval process all over again.) Is this really CMS's role?


Bladerunner